US research shows that a drug used to treat kidney cancer could successfully be used to treat patients with acute myeloid leukaemia.
New evidence on leukaemia treatment
Michael Andreef, from the University of Texas M.D. Anderson Cancer Centre, claims that an initial trial shows that Sorafenib attacks a gene mutation active in about a third of patients. It reduced the median percentage of leukaemia cells circulating in the blood from 81% to 7.5% and from 75.5% to 34% in bone marrow. In two of the patients, circulating leukaemia cells dropped to zero.
